The Winship Cancer Institute of Emory University (Winship) was awarded a type I Cancer Center Support Grant (CCSG) in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care. The 152 Winship members are actively engaged in one of four research programs: Cancer Genetics and Epigenetics, Cancer Cell Biology, Discovery and Developmental Therapeutics, and Cancer Prevention and Control. Winship's members are supported by five shared resources: Cell Imaging and Microscopy, Cancer Genomics, Biostatistics and Bioinformatics, Cancer Tissue and Pathology, and the Clinical Trials Office. Winship currently occupies more than 482k sq. ft. (sf) of dedicated clinical, research, and shared resource space under the direct control of the Executive Director, Walter J. Curran, Jr. M.D. Dr. Curran assumed this position in Sept. 2009 and under his leadership Winship completed a five-year strategic plan, a full reorganization of the senior leadership and administrative infrastructure, and an expansion of the pilot grant program to reward mentorship, inter-programmatic collaboration, innovation in clinical research, and outstanding junior investigators. Winship's 4 research programs have also undergone full re-evaluation and re-invigoration with the addition of several new program leaders and co-leaders, improved member alignment, more focused scientific themes, and greater program leader participation in cancer center decision-making and governance. Since its initial CCSG application Winship has experienced significant research growth and maturation. Total cancer-related peer-reviewed grant funding has increased 35% to $74.6 million, and NCI funding has increased 21% to $29.5 million. Currently there are 19 federally-supported multi-investigator cancer-relevant grants led by Winship members. Winship has outstanding institutional commitment, with more than $115 million in institutional support over the next five years (more than twice that committed in 2008), with its institutional status at the level of Emory's Schools of Medicine, Public Health, and Nursing. Plans are in place for an additional 57K sf of cancer research space. Patient enrollment in Winship's innovative therapeutic and non-therapeutic trials continues to increase, especially among patients from under-represented minority groups. Winship is well-positioned to leverage its growth and development as an NCI-designated cancer center into fulfilling its vision of transformative cancer research and care.
Winship was awarded a type I CCSG in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care.
|Qi, Q; Kang, S S; Zhang, S et al. (2017) Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression. Oncogene 36:4562-4572|
|Cornely, Ronald M; Schlingmann, Barbara; Shepherd, Whitney S et al. (2017) Two common human CLDN5 alleles encode different open reading frames but produce one protein isoform. Ann N Y Acad Sci 1397:119-129|
|Lee, Byoungkoo; Konen, Jessica; Wilkinson, Scott et al. (2017) Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics. Sci Rep 7:39498|
|Zhong, Jim; Patel, Kirtesh; Switchenko, Jeffrey et al. (2017) Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 123:3486-3493|
|Morris, Lydia P; Conley, Andrew B; Degtyareva, Natalya et al. (2017) Genome-wide map of Apn1 binding sites under oxidative stress in Saccharomyces cerevisiae. Yeast 34:447-458|
|Kim, Yong Joon; Kaluz, Stefan; Mehta, Anil et al. (2017) Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio Protoc 7:|
|Cassidy, Richard J; Liu, Yuan; Patel, Kirtesh et al. (2017) Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. Cancer 123:783-793|
|Gavile, Catherine M; Barwick, Benjamin G; Newman, Scott et al. (2017) CD86 regulates myeloma cell survival. Blood Adv 1:2307-2319|
|Ivanov, A A; Gonzalez-Pecchi, V; Khuri, L F et al. (2017) OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. Oncogene 36:5852-5860|
|Fei, Baowei; Guolan Lu; Halicek, Martin T et al. (2017) Label-free hyperspectral imaging and quantification methods for surgical margin assessment of tissue specimens of cancer patients. Conf Proc IEEE Eng Med Biol Soc 2017:4041-4045|
Showing the most recent 10 out of 265 publications